Precigen (PGEN) to Release Quarterly Earnings on Wednesday

Precigen (NASDAQ:PGEN) is expected to be issuing its Q4 2025 results before the market opens on Wednesday, March 18th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $8.2860 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 19, 2026 at 4:00 PM ET.

Precigen Price Performance

Shares of NASDAQ PGEN opened at $3.51 on Wednesday. The company has a quick ratio of 3.95, a current ratio of 4.04 and a debt-to-equity ratio of 2.22. Precigen has a 52 week low of $1.11 and a 52 week high of $5.47. The firm’s fifty day moving average is $4.33 and its 200 day moving average is $4.07. The company has a market cap of $1.24 billion, a price-to-earnings ratio of -2.53 and a beta of 1.10.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on PGEN shares. Wall Street Zen lowered shares of Precigen from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Zacks Research downgraded shares of Precigen from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 22nd. HC Wainwright increased their target price on shares of Precigen from $8.50 to $9.00 and gave the stock a “buy” rating in a report on Friday, November 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a research note on Thursday, January 22nd. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $8.50.

Insider Buying and Selling at Precigen

In other Precigen news, Director Randal J. Kirk sold 1,900,036 shares of the firm’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $4.18, for a total value of $7,942,150.48. Following the transaction, the director directly owned 341,189 shares of the company’s stock, valued at approximately $1,426,170.02. This trade represents a 84.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 47.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Precigen

A number of institutional investors have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd bought a new stake in Precigen in the third quarter worth $39,000. Russell Investments Group Ltd. bought a new stake in shares of Precigen during the 3rd quarter worth approximately $41,000. Mason Investment Advisory Services Inc. purchased a new stake in shares of Precigen during the fourth quarter valued at $42,000. Abel Hall LLC purchased a new stake in Precigen in the 4th quarter valued at about $44,000. Finally, NewEdge Advisors LLC purchased a new position in Precigen during the 4th quarter worth $45,000. 33.51% of the stock is owned by hedge funds and other institutional investors.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.